MED-OLMESARTAN TABLET

Country: Կանադա

language: անգլերեն

source: Health Canada

active_ingredient:

OLMESARTAN MEDOXOMIL

MAH:

GENERIC MEDICAL PARTNERS INC

ATC_code:

C09CA08

INN:

OLMESARTAN MEDOXOMIL

dosage:

20MG

pharmaceutical_form:

TABLET

composition:

OLMESARTAN MEDOXOMIL 20MG

administration_route:

ORAL

units_in_package:

2X14/100

prescription_type:

Prescription

therapeutic_area:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

leaflet_short:

Active ingredient group (AIG) number: 0152496002; AHFS:

authorization_status:

APPROVED

authorization_date:

2017-05-01

SPC

_Page 1 of 27_
PRODUCT MONOGRAPH
PR
MED-OLMESARTAN
Olmesartan Medoxomil Tablets
20 mg, and 40 mg olmesartan medoxomil,
Angiotensin II AT
1
Receptor
Blocker
GENERIC MEDICAL PARTNERS INC.
251 Consumers Road, Suite 1200
Toronto, Ontario
M2J 4R3
Date of Revision:
APRIL 24, 2017
Submission Control No: 178734, 204768
_Page 2 of 27_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
...................................................................................................
10
DOSAGE AND ADMINISTRATION
...............................................................................
12
OVERDOSAGE
.................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 14
STORAGE AND STABILITY
..........................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 16
PART II: SCIENTIFIC INFORMATION
................................................................................
17
PHARMACEUTICAL INFORMATION
...........................................................................
17
CLINICAL TRIALS
...........................................................................................................
18
DETAILED PHARMACOLOGY
............